GeneDx Holdings Corp

WGS is in a Stage 2 advance with a dominant Lockout Rally driving large, clean moves and minimal pullbacks. The 9- and 21-day EMAs remain rising and are providing dynamic support as price pulls back into that zone. With RSI and Options Score in neutral ranges and no overbought exhaustion, this shallow retracement into the EMAs offers a high-probability continuation entry. Caution around moderate Stage 2→3 transition risk and overhead supply is warranted.

• ↑Test volume surged 34% YoY to 27,488 in Q1.
• ↑Q1 revenue $102.3M (+17% YoY) with avg reimbursement ~$3,700/test.
• ↓$31.2M impairment led to multiple securities class-action lawsuits.